July 25, 2017 8:05 PM ET

Life Sciences Tools and Services

Company Overview of BioAtla, LLC

Company Overview

BioAtla, LLC, a global biology outsourcing services provider, offers protein therapeutics technology and services. It provides target discovery services; and antibody evolution, engineering, and generation services that include antibody affinity maturation and functional engineering, antibody expression and purification, assay development and functional characterization, antibody internalization, antigen expression and purification, monoclonal and polyclonal antibody production, and follow-on biologics services. The company also offers Versitope system that maximizes epitope coverage, affinity, and functionality to deliver the path to discovery of immunization-induced antibodies; GigaMab, a ...

11011 Torreyana Road

San Diego, CA 92121

United States

Founded in 2007

Phone:

858-558-0708

Fax:

858-558-0701

Key Executives for BioAtla, LLC

Founder, Chairman, Chief Executive Officer and President
Age: 59
Founder and Business Advisor
Age: 55
Chief Financial Officer
Age: 63
Chief Medical Officer
Compensation as of Fiscal Year 2017.

BioAtla, LLC Key Developments

BioAtla, LLC Appoints Yong Ben as Chief Medical Officer

BioAtla, LLC announced the appointment of Yong Ben, M.D., as chief medical officer. Dr. Ben, an experienced biotechnology drug developer in oncology, joins the Company from AstraZeneca, where he was most recently Global Clinical Lead, Immuno-Oncology. His clinical leadership in pharmaceutical and biotechnology companies led to several oncology drug approvals including, for AstraZeneca, the most recent approval of a PD-L1 antibody, durvalumab (Imfinzi), for the treatment of urothelial cancer, ixazomib (Ninlaro) in multiple myeloma for Millennium/Takeda, axitinib (Inlyta) in renal cancer for Pfizer, and oncolytic virus H101 in head and neck cancer for SunwayBio.

BioAtla Joins Forces with F1 Oncology

BioAtla and F1 Oncology reported a global license agreement to combine BioAtla's CAB technology with F1 Oncology's proprietary technologies to develop and commercialize chimeric antigen receptor T-cell (CAR-T) therapies and other ACTs for the treatment of cancer. BioAtla has granted F1 Oncology an exclusive worldwide license under patents and know-how controlled by BioAtla to discover, develop, manufacture and commercialize ACT preparations and treatments for cancer. The financial terms of this license to F1 Oncology include a mid-single digit royalty outside of China, Hong Kong, Macau and Taiwan (the Territory). Within the Territory, the license is royalty-free and fully paid, and BioAtla shares in the product revenue. In exchange for the license rights, as well as BioAtla's agreement not to compete in ACTs, BioAtla received a majority, non-controlling interest of the outstanding capital stock of F1 Oncology and has no funding or financial obligation. BioAtla also has a conditional and time-limited option to acquire at a fixed valuation all of the outstanding equity securities of F1 Oncology held by all other investors. BioAtla and F1 Oncology said that they have identified CAR-T and other ACT therapies as potential opportunities for the application of CAB technology. BioAtla has demonstrated in preclinical studies that CAB antibodies can be constructed in the same single chain format used by CAR-Ts and can retain their selectivity for binding under conditions representative of the tumor microenvironment (TME) and with minimal to no detectable binding in normal cell conditions. CARs are constructs that contain an antigenbinding domain of an antibody fused to a strong T-cell activator domain. T-cells modified with the CAR construct can bind to the antigen and be stimulated to attack the bound cells. On-target, off-tumor toxicity has largely limited current CAR-T therapies to target blood cancers such as leukemia and some lymphomas. While CAR-T related toxicities are multifactorial and complex, CAR-T cells containing CAB CAR domains targeting solid tumor antigens would be intended to reduce on-target, off-tumor toxicity and potentially increase patient safety.

BioAtla and F1 Oncology Announce Global Collaboration to Develop Adoptive Cellular Therapies for Solid Tumors

BioAtla, LLC and F1 Oncology Inc. announced a global license agreement to combine BioAtla's CAB technology with F1 Oncology's proprietary technologies to develop and commercialize chimeric antigen receptor T-cell (CAR-T) therapies and other ACTs for the treatment of cancer.  F1 Oncology recently completed a $37 million Series A financing led by F1 BioVentures LLC, Sinobioway Group, and SunTerra Capital. Through its international affiliates, F1 Oncology also entered into a development and commercialization agreement with Shanghai SunTerra Biotechnology Ltd. and its network of academic investigators to enable clinical investigation of CAB CAR-T candidates in China. F1 Oncology's partners intend to begin clinical trials in China in 2017 targeting a solid tumor indication using F1's first CAB CAR-T therapy candidate. The financial terms of this agreement include technical and regulatory milestone-based equity investments of up to $50 million through 2018, as well as supply-related payments by target and indication.  F1 Oncology retains rights to all products outside China, Hong Kong, Macau and Taiwan. BioAtla and F1 Oncology have identified CAR-T and other ACT therapies as potential opportunities for the application of CAB technology. BioAtla has demonstrated in preclinical studies that CAB antibodies can be constructed in the same single chain format used by CAR-Ts and can retain their selectivity for binding under conditions representative of the tumor microenvironment (TME) and with minimal to no detectable binding in normal cell conditions. CARs are constructs that contain an antigen–binding domain of an antibody fused to a strong T-cell activator domain. T-cells modified with the CAR construct can bind to the antigen and be stimulated to attack the bound cells. On-target, off-tumor toxicity has largely limited current CAR-T therapies to target blood cancers such as leukemia and some lymphomas.  While CAR-T related toxicities are multifactorial and complex, CAR-T cells containing CAB CAR domains targeting solid tumor antigens would be intended to reduce on-target, off-tumor toxicity and potentially increase patient safety.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BioAtla, LLC, please visit www.bioatla.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.